Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
One offers broad diversification at 0.08% cost, while the other targets concentrated biotech growth with higher volatility.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.